← Oncology Approval Tracker

FDA DECISION ·

Breyanzi

lisocabtagene maraleucel · Juno Therapeutics (Bristol Myers Squibb)

Accelerated approvalNew or expanded indicationChronic lymphocytic leukemia and small lymphocytic lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory CLL or SLL after at least two prior treatment lines, including a BTK inhibitor and a BCL-2 inhibitor.

LAMPGEN ANALYSIS

Why it matters

The label added a CD19 CAR T option after exposure to both major targeted drug classes.

What research teams should watch

Identify patients early enough for cell collection and record the reasons and dates for discontinuing prior targeted treatments.

PRIMARY RECORDS

Sources